Hyperuricaemia: More than just a cause of gout?

Journal of Cardiovascular Medicine

Volumn 14, Issue 6, 2013, Pages 397-402

  Katsiki, Niki ^a   Karagiannis, Asterios ^a   Athyros, Vasilios G ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular disease; Gout; Metabolic syndrome; Renal disease; Uric acid; Vascular risk

Indexed keywords

ALDOSTERONE; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; FEBUXOSTAT; FENOFIBRATE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ACUTE KIDNEY FAILURE; ANKLE BRACHIAL INDEX; AORTA ANEURYSM; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL PROLIFERATION; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FUNCTIONAL STATUS; GLOMERULUS FILTRATION RATE; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; MEDITERRANEAN DIET; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PULSE WAVE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; GOUT; HUMANS; HYPERURICEMIA; INFLAMMATION; KIDNEY DISEASES; MALE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; URIC ACID;

EID: 84879503848     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283595adc     Document Type: Review

References (143)

1. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011; 13:160- 166.
2. Chilappa CS, Aronow WS, Shapiro D, et al. Gout and hyperuricemia. Compr Ther 2010; 36:3-13.
3. Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol 2011; 23:156-160.
4. Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the populationbased Colaus study. PLoS One 2011; 6:e19901.
5. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005; 25:39-42. (Pubitemid 40128147)
6. Vekic J, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, et al. High serum uric acid and low-grade inflammation are associated with smaller LDL and HDL particles. Atherosclerosis 2009; 203:236-242.
7. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford) 2010; 49:1229-1238.
8. Sonoda H, Takase H, Dohi Y, et al. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol 2011; 33:352- 357.
9. Carrero JJ, Stenvinkel P. Predialysis chronic kidney disease in 2010: novel targets for slowing CKD progression. Nat Rev Nephrol 2011; 7:65-66.
10. Park SH, Shin WY, Lee EY, et al. The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circ J 2011; 75:692- 697.
11. Zhou Y, Fang L, Jiang L, et al. Uric acid induces renal inflammation via activating tubular NF-kB signaling pathway. PLoS One 2012; 7:e39738.
12. ShimadaM, Dass B, Ejaz AA. Paradigm shift in the role of uric acid in acute kidney injury. Semin Nephrol 2011; 31:453-458.
13. Knoll T, Schubert AB, Fahlenkamp D, et al. Urolithiasis through the ages: data on more than 200 000 urinary stone analyses. J Urol 2011; 185:1304-1311.
14. Chou YH, Li CC, Hsu H, et al. Renal function in patients with urinary stones of varying compositions. Kaohsiung J Med Sci 2011; 27:264- 267.
15. Wagner CA, Mohebbi N. Urinary pH and stone formation. J Nephrol 2010; 23 (Suppl 16):S165-S169.
16. Hall PM. Nephrolithiasis: treatment, causes, and prevention. Cleve Clin J Med 2009; 76:583-591.
17. Strohmaier WL, Wrobel BM, Schubert G. Overweight, insulin resistance and blood pressure (parameters of the metabolic syndrome) in uric acid urolithiasis. Urol Res 2012; 40:171-175.
18. Kawano Y. Uric acid and blood pressure. Circ J 2011; 75:2755- 2756.
19. Kansui Y, Ohtsubo T, Goto K, et al. Association of serum uric acid with blood pressure in Japanese men. Circ J 2011; 75:2827-2832.
20. Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol 2009; 21:132-137.
21. Bandaru P, Shankar A. Association between serum uric acid levels and diabetes mellitus. Int J Endocrinol 2011; 2011:604715.
22. Hikita M, Ohno I, Mori Y, et al. Relationship between hyperuricemia and body fat distribution. Intern Med 2007; 46:1353-1358. (Pubitemid 47455757)
23. Ito H, Abe M, Mifune M, et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS One 2011; 6:e27817.
24. Papanas N, Demetriou M, Katsiki N, et al. Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus. Exp Diabetes Res 2011; 2011:346051.
25. Papanas N, Katsiki N, Papatheodorou K, et al. Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology 2011; 62:291-295.
26. Hovind P, Rossing P, Johnson RJ, et al. Serum uric acid as a new player in the development of diabetic nephropathy. J Ren Nutr 2011; 21:124- 127.
27. Cai XL, Wang F, Ji LN. Risk factors of diabetic retinopathy in type 2 diabetic patients. Chin Med J (Engl) 2006; 119:822-826. (Pubitemid 43796811)
28. Tanaka K, Hara S, Kushiyama A, et al. Risk of macrovascular disease stratified by stage of chronic kidney disease in type 2 diabetic patients: critical level of the estimated glomerular filtration rate and the significance of hyperuricemia. Clin Exp Nephrol 2011; 15:391-397.
29. Newman EJ, Rahman FS, Lees KR, et al. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diab Metab Res Rev 2006; 22:79-82. (Pubitemid 43154466)
30. Zhang Z, Bian L, Choi Y. Serum uric acid: a marker of metabolic syndrome and subclinical atherosclerosis in Korean men. Angiology 2012; 63:420- 428.
31. Borges RL, Ribeiro AB, Zanella MT, et al. Uric acid as a factor in the metabolic syndrome. Curr Hypertens Rep 2010; 12:113-119.
32. Lee JM, Kim HC, Cho HM, Oh SM, Choi DP, Suh I. Association between serum uric acid level and metabolic syndrome. J Prev Med Public Health 2012; 45:181-187.
33. Puig JG, Martínez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008; 20:187-191. (Pubitemid 351339891)
34. Haj Mouhamed D, Ezzaher A, Neffati F, et al. Effect of cigarette smoking on plasma uric acid concentrations. Environ Health Prev Med 2011; 16:307-312.
35. Tomita M, Mizuno S, Yokota K. Increased levels of serum uric acid among ex-smokers. J Epidemiol 2008; 18:132-134.
36. Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2011; 56:35-45.
37. Perseghin G. The role of nonalcoholic fatty liver disease in cardiovascular disease. Dig Dis 2010; 28:210-213.
38. Katsiki N, Athyros VG, Karagiannis A, et al. Hyperuricaemia and nonalcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9:698-705.
39. Xu C, Yu C, Xu L, et al. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS One 2010; 5:e11578.
40. Lee JW, Cho YK, Ryan M, et al. Serum uric acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver 2010; 4:378- 383.
41. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009; 25:567-579.
42. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769- 1818.
43. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol 2012. [Epub ahead of print]
44. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with nonalcoholic fatty liver disease: is there a link? J Hepatol 2011; 54:1020-1029.
45. Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 2012; 35:99-104.
46. Tangri N, Weiner DE. Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles. Am J Kidney Dis 2010; 56:247-250.
47. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009; 18:526-530.
48. Kang DH, Chen W. Uric acid and chronic kidney disease: new understanding of an old problem. Semin Nephrol 2011; 31:447-452.
49. Mok Y, Lee SJ, Kim MS, Cui W, Moon YM, Jee SH. Serum uric acid and chronic kidney disease: the Severance cohort study. Nephrol Dial Transplant 2012; 27:1831-1835.
50. Jolly SE, Mete M, Wang H, et al. Uric acid, hypertension, and chronic kidney disease among Alaska Eskimos: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. J Clin Hypertens (Greenwich) 2012; 14:71-77.
51. Neri L, Rocca Rey LA, Lentine KL, et al. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis 2011; 58:398-408.
52. Meisinger C, Koenig W, Baumert J, et al. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/ KORA cohort study. Arterioscler Thromb Vasc Biol 2008; 28:1186- 1192.
53. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61:885- 892.
54. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62:170-180.
55. Neri L, Rocca Rey LA, Lentine KL, et al. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis 2011; 58:398-408.
56. Nam GE, Lee KS, Park YG, et al. An increase in serum uric acid concentrations is associated with an increase in the Framingham risk score in Korean adults. Clin Chem Lab Med 2011; 49:909-914.
57. Milionis HJ, Kalantzi KJ, Goudevenos JA, et al. Serum uric acid levels and risk for acute ischaemic nonembolic stroke in elderly subjects. J Intern Med 2005; 258:435-441. (Pubitemid 41546559)
58. Karagiannis A, Mikhailidis DP, Tziomalos K, et al. Serum uric acid as an independent predictor of early death after acute stroke. Circ J 2007; 71:1120-1127. (Pubitemid 46998030)
59. Silbernagel G, Hoffmann MM, Grammer TB, et al. Uric acid is predictive of cardiovascular mortality and sudden cardiac death in subjects referred for coronary angiography. Nutr Metab Cardiovasc Dis 2011. [Epub ahead of print]
60. Strasak AM, Kelleher CC, Brant LJ, et al., VHM & PP Study Group. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28, 613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008; 125:232-239.
61. Kawai T, Ohishi M, Takeya Y, et al. Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients. Hypertens Res 2012. doi:10.1038/hr.2012.99. [Epub ahead of print]
62. Duran M, Kalay N, Akpek M, et al. High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome. Angiology 2012; 63:448-452.
63. Sinan Deveci O, Kabakci G, Okutucu S, et al. The association between serum uric acid level and coronary artery disease. Int J Clin Pract 2010; 64:900-907.
64. Kaya MG, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2012; 109:486-491.
65. Ndrepepa G, Braun S, King L, et al. Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism 2012. [Epub ahead of print]
66. Duran M, Ornek E, Murat SN, et al. High levels of serum uric acid impair development of coronary collaterals in patients with acute coronary syndrome. Angiology 2012; 63:472-475.
67. Sen T, Aksu T. Serum uric acid level as a part of the metabolic syndrome impairs the coronary collateral formation. Angiology 2012; 63:476-477.
68. Gerber Y, Tanne D, Medalie JH, et al. Serum uric acid and long-term mortality from stroke, coronary heart disease and all causes. Eur J Cardiovasc Prev Rehabil 2006; 13:193-198. (Pubitemid 44097723)
69. Seet RC, Kasiman K, Gruber J, et al. Is uric acid protective or deleterious in acute ischemic stroke? A prospective cohort study. Atherosclerosis 2010; 209:215-219.
70. Logallo N, Naess H, Idicula TT, et al. Serum uric acid: neuroprotection in thrombolysis. The Bergen NORSTROKE study. BMC Neurol 2011; 11:114.
71. Suliman ME, Johnson RJ, García-López E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006; 48:761-771. (Pubitemid 44740052)
72. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008; 27:608-619. (Pubitemid 351948591)
73. Li Q, Yang Z, Lu B, et al. Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 2011; 10:72.
74. Riccioni G, D'Orazio N, Palumbo N, et al. Relationship between plasma antioxidant concentrations and carotid intima-media thickness: the Asymptomatic Carotid Atherosclerotic Disease In Manfredonia Study. Eur J Cardiovasc Prev Rehabil 2009; 16:351-357.
75. Pacifico L, Cantisani V, Anania C, et al. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. Eur J Endocrinol 2009; 160:45-52.
76. Tavil Y, Kaya MG, Oktar SO, et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis 2008; 197:159-163. (Pubitemid 351273235)
77. Montalcini T, Gorgone G, Gazzaruso C, et al. Relation between serum uric acid and carotid intima-media thickness in healthy postmenopausal women. Intern Emerg Med 2007; 2:19-23.
78. Kawamoto R, Tomita H, Oka Y, et al. Association between uric acid and carotid atherosclerosis in elderly persons. Intern Med 2005; 44:787- 793. (Pubitemid 41263821)
79. Viazzi F, Parodi D, Leoncini G, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005; 45:991- 996. (Pubitemid 40628949)
80. Neogi T, Ellison RC, Hunt S, et al. Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute Family Heart Study. J Rheumatol 2009; 36:378-384.
81. Esen AM, Akcakoyun M, Esen O, et al. Uric acid as a marker of oxidative stress in dilatation of the ascending aorta. Am J Hypertens 2011; 24:149-154.
82. Vlachopoulos C, Xaplanteris P, Vyssoulis G, et al. Association of serum uric acid level with aortic stiffness and arterial wave reflections in newly diagnosed, never-treated hypertension. Am J Hypertens 2011; 24:33- 39.
83. Chen X, Li Y, Sheng CS, et al. Association of serum uric acid with aortic stiffness and pressure in a Chinese workplace setting. Am J Hypertens 2010; 23:387-392.
84. Kuo CF, Yu KH, Luo SF, et al. Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study. Rheumatology (Oxford) 2010; 49:1189-1196.
85. Erdogan D, Gullu H, Caliskan M, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005; 59:1276-1282. (Pubitemid 43904496)
86. Fukui M, Tanaka M, Shiraishi E, et al. Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. Metabolism 2008; 57:625-629. (Pubitemid 351608223)
87. Ishizaka N, Ishizaka Y, Toda E, et al. Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis 2007; 192:131-137. (Pubitemid 46602289)
88. Shin JY, Lee HR, Shim JY. Significance of high-normal serum uric acid level as a risk factor for arterial stiffness in healthy Korean men. Vasc Med 2012; 17:37-43.
89. Lim JH, Kim YK, Kim YS, et al. Relationship between serum uric acid levels, metabolic syndrome, and arterial stiffness in Koreans. Korean Circ J 2010; 40:314-320.
90. Tsioufis C, Kyvelou S, Dimitriadis K, et al. The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives. J Hum Hypertens 2011; 25:554-559.
91. Demir B, Caglar IM, Ugurlucan M, et al. The relationship between severity of calcific aortic stenosis and serum uric acid levels. Angiology 2012 [Epub ahead of print].
92. Saitoh S. Uric acid and left ventricular hypertrophy. Circ J 2009; 73:624- 625.
93. Gluba A, Bielecka A, Mikhailidis DP, et al. An update on biomarkers of heart failure in hypertensive patients. J Hypertens 2012; 30:1681- 1689.
94. Tamariz L, Agarwal S, Soliman EZ, et al. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011; 108:1272-1276.
95. Liu T, Zhang X, Korantzopoulos P, et al. Uric acid levels and atrial fibrillation in hypertensive patients. Intern Med 2011; 50:799-803.
96. Tekin G, Tekin YK, Erbay AR, Turhan H, Yetkin E. Serum uric acid levels are associated with atrial fibrillation in patients with ischemic heart failure. Angiology 2012. [Epub ahead of print]
97. Zheng L, Yu J, Li J, et al. Prevalence of and risk factors for peripheral arterial disease among Chinese hypertensive patients with and without known cardiovascular disease. Acta Cardiol 2008; 63:693-699.
98. Shankar A, Klein BE, Nieto FJ, et al. Association between serum uric acid level and peripheral arterial disease. Atherosclerosis 2008; 196:749- 755. (Pubitemid 351146654)
99. Tseng CH. Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with Type 2 diabetes. Diabet Med 2004; 21:724-729.
100. Langlois M, De Bacquer D, Duprez D, et al. Serum uric acid in hypertensive patients with and without peripheral arterial disease. Atherosclerosis 2003; 168:163-168. (Pubitemid 36555824)
101. Maksimovic M, Vlajinac H, Radak D, Marinkovic J, Jorga J. Relationship between high-sensitivity C-reactive protein and risk factors in patients with peripheral arterial disease: a cross-sectional study. Angiology 2012. [Epub ahead of print]
102. Li X, Wang YZ, Yang XP, et al. The prevalence and risk factors of an abnormal ankle-brachial index in patients with type 2 diabetes. J Diabetes 2012; 4:140-146.
103. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 2007; 58:450-457. (Pubitemid 47301052)
104. Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 2001; 87:1411- 1414. (Pubitemid 32523032)
105. Viazzi F, Leoncini G, Ratto E, et al. Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revised. J Clin Hypertens 2006; 8:510-518.
106. Høieggen A, Alderman MH, Kjeldsen SE, et al., LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65:1041-1049. (Pubitemid 38251080)
107. Koton S, Howard SC, Warlow CP, et al. Serum urate predicts long-term risk of acute coronary events in women after a transient ischaemic attack and stroke. Cerebrovasc Dis 2008; 26:517-524.
108. Krzystek-Korpacka M, Patryn E, Kustrzeba-Wojcicka I, et al. Altered uric acid levels and disease states. J Pharmacol Exp Ther 2008; 324:1-7.
109. Zhang Q, Lou S, Meng Z, et al. Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese. Clin Rheumatol 2011; 30:777-787.
110. Kuwahata S, Hamasaki S, Ishida S, et al. Effect of uric acid on coronary microvascular endothelial function in women: association with eGFR and ADMA. J Atheroscler Thromb 2010; 17:259-269.
111. Tseng CH. Sex difference in the distribution of atherosclerotic risk factors and their association with peripheral arterial disease in Taiwanese type 2 diabetic patients. Circ J 2007; 71:1131-1136.
112. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther 2008; 324:1-7. (Pubitemid 350294141)
113. Spitsin S, Koprowski H. Role of uric acid in multiple sclerosis. Curr Top Microbiol Immunol 2008; 318:325-342.
114. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med 2010; 4:701-712.
115. Maetzler W, Stapf AK, Schulte C, et al. Serum and cerebrospinal fluid uric acid levels in Lewy body disorders: associations with disease occurrence and amyloid-b pathway. J Alzheimers Dis 2011; 27:119-126.
116. Liu B, Shen Y, Xiao K, Tang Y, Cen L, Wei J. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol Res 2012; 34:163-171.
117. Euser SM, Hofman A, Westendorp RG, et al. Serum uric acid and cognitive function and dementia. Brain 2009; 132 (Pt 2):377-382.
118. Bowman GL, Shannon J, Frei B, et al. Uric acid as a CNS antioxidant. J Alzheimers Dis 2010; 19:1331-1336.
119. Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 2010; 22:165-172.
120. Siebenhofer A, Jeitler K, Berghold A, et al. Long-term effects of weightreducing diets in hypertensive patients. Cochrane Database Syst Rev 2011; 9:CD008274.
121. Wing RR, Lang W, Wadden TA, et al., Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diab Care 2011; 34:1481-1486.
122. Janosz KE, Zalesin KC, Miller WM, et al. Impact of surgical and nonsurgical weight loss on diabetes resolution and cardiovascular risk reduction. Curr Diab Rep 2009; 9:223-228.
123. Katcher HI, Hill AM, Lanford JL, et al. Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDLcholesterol. Endocrinol Metab Clin North Am 2009; 38:45-78.
124. Kontogianni M, Chrysohoou C, Panagiotakos D, et al. Adherence to the Mediterranean diet and serum uric acid: the ATTICA study. Scand J Rheumatol 2012. [Epub ahead of print]
125. Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev 2011; 19:265-271.
126. Love BL, Barrons R, Veverka A, et al. Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy 2010; 30:594-608.
127. Daskalopoulou SS, Athyros VG, Elisaf M, et al. Uric acid levels and vascular disease. Curr Med Res Opin 2004; 20:951-954. (Pubitemid 38821534)
128. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, et al. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005; 11:4161-4175. (Pubitemid 41679180)
129. Derosa G, Maffioli P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Rev Cardiovasc Ther 2010; 8:835-843.
130. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005; 21:1997-2006. (Pubitemid 41803111)
131. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21:457- 468.
132. Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006; 22:1123-1131. (Pubitemid 44000732)
133. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Nephrol Dial Transplant 2007; 22:118-127. (Pubitemid 46050336)
134. Youssef F, Gupta P, Seifalian AM, et al. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004; 55:53-62. (Pubitemid 38082539)
135. Rizos CV, Liberopoulos EN, Mikhailidis DP, et al. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008; 9:1087-1108. (Pubitemid 351721748)
136. Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55:1293-1301. (Pubitemid 44354944)
137. Moutzouri E, Liberopoulos EN, Florentin M, Liamis G, Elisaf MS. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. J Cardiovasc Pharmacol Ther 2012. [Epub ahead of print]
138. Ansquer JC, Dalton RN, Caussé E, Crimet D, Le Malicot K, Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008; 51:904-913. (Pubitemid 351697561)
139. Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin Investig Drugs 2010; 19:1581-1589.
140. Florentin M, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol 2011; 9:385-400.
141. Athyros VG, Elisaf M, Papageorgiou AA, et al. GREACE Study Collaborative Group: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease. A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43:589-599. (Pubitemid 38401873)
142. Athyros VG, Hatzitolios AI, Karagiannis A, et al., for the IMPERATIVE Collaborative Group. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011; 7:984-992.
143. Athyros VG, Karagiannis A, Ganotakis ES, et al., Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27:1659-1668.